Compare Abbott Laboratories (ABT) vs CarMax, Inc (KMX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs CarMax, Inc — how do they compare? Abbott Laboratories trades at $95.36 (market cap $166.94B), while CarMax, Inc trades at $50.37 (market cap $7.24B). The key difference: Abbott Laboratories is far larger — about 23.1× CarMax, Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.
| ABT | KMX | |
|---|---|---|
Market Cap | $166.94B | $7.24B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $68.38 |
52-Week Low | $82.57 | $30.88 |
Enterprise Value | $193.69B | $25.75B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
CarMax (KMX) trades at $51.05, up 0.14% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 earnings that beat expectations, with revenue growth and cost control supporting a net income margin of 0.84%. Recent news highlights insider buying and a four-pillar turnaround strategy under new CEO Keith Barr, though margins remain under pressure.
The outlook is mixed: analyst consensus is cautious with a hold-heavy rating and $48.91 price target below current levels, but improving cash flow and strategic initiatives offer potential upside. Key risks include persistent margin compression, high debt levels, and execution challenges in a competitive used car market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
